Drug-eluting bead therapy in primary and metastatic disease of the liver
- 1 November 2009
- journal article
- Published by Elsevier BV in HPB
- Vol. 11 (7), 541-550
- https://doi.org/10.1111/j.1477-2574.2009.00071.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead™Expert Review of Anticancer Therapy, 2008
- Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical studyJournal of Hepatology, 2008
- Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study.2008
- Irinotecan drug eluting beads for use in chemoembolization: In vitro and in vivo evaluation of drug release propertiesEuropean Journal of Pharmaceutical Sciences, 2007
- Evaluation of irinotecan drug-eluting beads: A new drug–device combination product for the chemoembolization of hepatic metastasesJournal of Controlled Release, 2006
- Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000